US Stock MarketDetailed Quotes

TEVA Teva Pharmaceutical Industries

Watchlist
  • 16.320
  • -0.460-2.74%
Close Feb 27 16:00 ET
  • 16.360
  • +0.040+0.24%
Post 20:01 ET
18.70BMarket Cap-11.26P/E (TTM)

About Teva Pharmaceutical Industries Company

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Company Profile

SymbolTEVA
Company NameTeva Pharmaceutical Industries
Listing DateMay 30, 2012
Founded1901
CEOMr. Richard D. Francis
MarketNYSE
Employees36830
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address124 Dvora HaNevi'a Street
CityTel Aviv
ProvinceTel Aviv
CountryIsrael
Zip Code6944020
Phone972-3-914-8213

Company Executives

  • Name
  • Position
  • Salary
  • Richard D. Francis
  • Director, President and Chief Executive Officer
  • --
  • Eli Kalif
  • Executive Vice President and Chief Financial Officer
  • 4.94M
  • Dr. Eric A Hughes, M.D.
  • Executive Vice President, Global R&D and Chief Medical Officer
  • --
  • David R. McAvoy
  • Executive Vice President and Chief Legal Officer
  • --
  • Amir Weiss
  • Senior Vice President and Chief Accounting Officer
  • --
  • Matthew Shields
  • Executive Vice President, Global Operations
  • --
  • Angus Grant
  • Executive Vice President, Business Development
  • --
  • Richard Daniell
  • Executive Vice President, European Commercial
  • 5.16M
  • Mark Sabag
  • Executive Vice President, International Markets Commercial
  • 3.73M
  • Christine Fox
  • Executive Vice President, U.S. Commercial
  • --
  • Dr. Sol J. Barer,PhD
  • Chairman of the Board
  • 539.99K
  • Gerald M. Lieberman
  • Independent Director
  • 355.00K
  • Dr. Perry D. Nisen
  • Independent Director
  • 327.87K
  • Roberto A. Mignone
  • Independent Director
  • 340.00K
  • Rosemary A. Crane, M.B.A.
  • Independent Director
  • 330.00K
  • Professor Ronit Satchi-Fainaro
  • Independent Director
  • 315.25K
  • Janet S. Vergis
  • Independent Director
  • 325.46K
  • Professor Varda Shalev
  • Independent Director
  • 176.66K
  • Amir Elstein
  • Independent Director
  • 340.00K
  • Chen Lichtenstein
  • Independent Director
  • --
  • Dr. Tal Zaks, M.D.,PhD
  • Independent Director
  • 330.00K
  • Vikki L. Conway
  • Acting Head of Global Human Resources
  • --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.